OncoCyte Corporation, a leading molecular diagnostics company based in Irvine, California, is making waves in the detection of cancer. With a focus on research, development, and commercialization of proprietary laboratory-developed tests, OncoCyte is quickly gaining recognition for its cutting-edge technologies. Among its offerings are DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression assay. The company also provides a range of other services, including biomarker discovery testing, assay design and development, biopharma, and clinical trial support services. Additionally, OncoCyte has engaged in a notable collaboration agreement with Life Technologies Corporation to develop and commercialize Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. Since its incorporation in 2009, this innovative company has been making significant strides in the fight against cancer both in the United States and abroad.
OncoCyte's ticker is OCX
The company's shares trade on the TSX stock exchange
They are based in Toronto, Ontario
There are 51-200 employees working at OncoCyte
It is oncocyte.com
OncoCyte is in the Conglomerates industry
The following five companies are OncoCyte's industry peers:
- Seven Group Holdings Limited